Evidence map›Paper›PMID 42626349›Full record

ArticleCureus2026

Encephalitis, High-Grade Atrioventricular Block, Acute Kidney Injury, and Hepatitis Following Atezolizumab Therapy: A Complex Case of Sequential Multiorgan Immune Checkpoint Inhibitor-Related Adverse Events.

Umar Ismail, Bello Makama Tijjani, Susmitha D Jagadeesha

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Umar IsmailInternal Medicine, Hywel Dda University Health Board, Pembrokeshire, GBR.
Bello Makama TijjaniGeneral Practice, St. Helens and Knowsley NHS Foundation Trust, Manchester, GBR.
Susmitha D JagadeeshaInternal Medicine, Hywel Dda University Health Board, Pembrokeshire, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) can cause serious toxicities due to widespread immune activation. We report the case of a 49-year-old man with lung cancer who presented with confusion and seizures 16 days after receiving atezolizumab. Investigations were unrevealing of a cause. Immunotherapy-related encephalitis was suspected, given the temporal association between symptoms and atezolizumab infusion. Despite treatment with antimicrobials and methylprednisolone, the patient developed ventricular standstill requiring cardiac pacing. Although neurology and cardiac rhythm improved with high-dose methylprednisolone and pacemaker insertion, the patient developed hepatitis and acute kidney injury (AKI) during steroid tapering, which resolved with re-escalation. This case highlights a potential life-threatening multiorgan dysfunction that can complicate ICI therapy. While established toxicity phenotypes present with synchronous multiorgan involvement, atypical cases may present with sequential organ involvement that can pose significant diagnostic challenges. This reinforces the need for vigilance and early multidisciplinary team coordination to ensure timely diagnosis and good outcomes.

Indexed as

3rd degree heart blockatezolizumabcardio-oncologyencephalitishepatitisiciimmune-related adverse event (irae)nephritisneuro oncology

Identifiers

PMID42626349
PMCPMC13492724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.